MedTrace Logo

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

NCT06209736 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-07-15

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)

Conditions

  • C3 Glomerulopathy
  • Idiopathic Immune Complex-Mediated Glomerulonephritis

Interventions

DRUG

OMS906 study drug

OMS906 study drug dose 5mg/kg IV administration at 4-week internals

Sponsors & Collaborators

  • Omeros Corporation

    lead INDUSTRY

Principal Investigators

  • Steve Whitaker, MD · Omeros Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2026-01-31
Completion
2026-04-30
FDA Drug
Yes

Countries

  • Lithuania
  • New Zealand
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06209736 on ClinicalTrials.gov